AIDS-related Kaposi’s sarcoma

Liposomal encapsulation of DOX or DNR Preferred anthracycline delivery to the tumor Breast cancer, ovarian cancer, AIDS-related Kaposi s sarcoma, multiple myeloma (pegylated liposomal DOX). Breast cancer (uncoated liposomal DOX). AIDS-related Kaposi s sarcoma, acute mye-loblastic leukemia, multiple myeloma, non-Hodgkin s lymphomas (uncoated liposomal DNR)... [Pg.95]

Ovarian cancer, breast cancer, AIDS-related Kaposi s sarcoma... [Pg.586]

Intron A interferon a-2b Schering-Plough Hairy cell leukemia, genital warts, AIDS-related Kaposi s sarcoma, hepatitis C, hepatitis B, malignant melanoma, follicular lymphoma in conjunction with chemotherapy... [Pg.694]

Hairy cell leukaemia Renal cell carcinoma Basal cell carcinoma Malignant melanoma AIDS-related Kaposi s sarcoma Multiple myeloma Chronic myelogenous leukaemia Non-Hodgkin s lymphoma... [Pg.226]

Hairy cell leukemia Genital warts AIDS-related Kaposi s sarcoma Non-A non-B hepatitis Hepatitis B Malignant melanoma Chronic viral hepatitis C Follicular lymphoma with chemotherapy June 1986 June 1988 Nov. 1988 Feb. 1991 July 1992 Dec. 1995 March 1997 Nov. 1997... [Pg.146]

Cheung TW, Remick SC, Azarnia N, Proper JA, Barrueco JR, Dezube BJ. AIDS-related Kaposi s sarcoma a phase II study of liposomal doxorubicin. The TLC D-99 Study Group. Clin Cancer Res 1999 5 3432. [Pg.47]

Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi s sarcoma. Drugs 1997 53 520. [Pg.47]

Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi s sarcoma results of a randomized phase III clinical trial. J Clin Oncol 1998 16 2445. [Pg.48]

Bristol-Myers Squibb Co. manufactures and distributes paclitaxel (brand name, Taxol, and generically known as taxol), which the FDA has approved for treatment of ovarian, breast and lung cancers and AIDs-related Kaposi s sarcoma. Bristol s patent listings in the Orange Book and the related patent infringement suits demonstrate that invalid patents in combination with the lengthy pendency of a patent application can potentially generate an additional 30-month stay. [Pg.119]

There are three liposomal forms of doxorubicin or daunorubicin on the market (Table 8.6). Doxil and DaunoXome have been approved for the treatment of AIDS-related Kaposi s sarcoma and are being evaluated in clinical trials for the treatment of a variety of cancers [148-151]. Evacet (liposomal doxorubicin) has recently been tested in large phase II and III clinical trials for the treatment of metastatic breast cancer and is awaiting approval by the FDA [151], Data obtained from trials thus far suggest that all three liposomal drugs offer significant therapeutic benefit compared with the free drug [113]. [Pg.225]

Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi s sarcoma. J Clin Pharmacol 1996 36 55-63. [Pg.202]

Alpha interferon is also effective in the treatment of hairy cell leukaemia, condyloma acuminata (caused by papilloma virus), chronic myelogenous leukaemia and AIDS related Kaposi s sarcoma. [Pg.342]

It is indicated in hairy cell leukemia, AIDS related Kaposi s sarcoma (the detailed pharmacology and its use as antiviral agent is discussed in chapter Antiviral agents ). [Pg.379]

Indications Treatment of chronic hepatitis C, hairy-cell leukemia and AIDS-related Kaposi s sarcoma, as well as for the treatment of chronic phase, Philadelphia chromosome-positive chronic myelogenous leukemia (CML)... [Pg.190]

Recommended dosage and monitoring requirements The recommended dose of Roferon-A for chronic hepatitis C is 3 million international units (MIU) three times a week for 12 months. The recommended dose for CML is 9 MIU daily optimal duration of therapy has not been determined. The recommended dose for hairy cell leukemia is 3 MIU daily for 16 to 24 weeks. The recommended dose for AIDS-related Kaposi s sarcoma is 36 MIU daily for 10 to 12 weeks. There are five types of interferon alfa currently available in the United States interferon alfa-2a, peginterferon alfa-2a, interferon alfa-2b, interferon alfacon-1, and interferon alfa n3. Doses are not consistent for these preparations. [Pg.190]

E. Therapeutic response According to the product label, studies have shown that Rofewn-A can normalize serum transaminases, improve Uver histology, and reduce viral load in patients with chronic hepatitis C virus (HCV) infection. Other studies have shown that Roferon-A can produce clinically meaningful tumor regression or disease stabilization in patients with hairy-cell leukemia or in patients with AIDS-related Kaposi s sarcoma. In Ph-positive CML, Roferon-A supplemented with intermittent chemotherapy has been shown to prolong overall survival and to delay disease progression compared to patients treated with chemotherapy alone. In addition Roferon-A has been shown to produce sustained complete cytogenetic responses in a small subset of patients with CML in chronic phase. [Pg.191]

F. Role in therapy According to Micromedex, Roferon-A is recommended as the drug of choice in renal carcinoma and the chronic phase of chronic myelogenous leukemia. The role of Gleevec (Ima-tinib) in CML is yet to be determined, but it may replace the use of interferon alfa-2a. Roferon-A is an alternative (for unrespon-sive/intolerant patients) to current regimens of choice in hairy-cell leukemia, multiple myeloma, metastatic melanoma, and AIDS-related Kaposi s sarcoma. Other alpha interferons appear to have similar efficacy and can be used in lieu of Roferon-A in some instances. In particular, interferon alfa-2b (Intron) can be considered to have the same role as interferon alfa-2a in chronic hepatitis C, Kaposi s sarcoma, and hairy-cell leukemia. [Pg.191]

H. Other considerations Interferon alfa-2a has been designated an orphan drug product for the treatment of chronic myelogenous leukemia, AIDS-related Kaposi s sarcoma, renal cell carcinoma, metastatic malignant melanoma, and esophageal and colorectal cancer. [Pg.192]

Indications Treatment of patients with hairy-cell leukemia, malignant melanoma, follicular non-Hodgkin s lymphoma (NHL), AIDS-related Kaposi s sarcoma, chronic hepatitis C, and the skin disorder, condylomata acuminata... [Pg.192]

Alitretinoin (Panretin) is a topical formulation of 9-c/s-retinoic acid which is approved for the treatment of cutaneous lesions in patients with AIDS-related Kaposi s sarcoma. Localized reactions may include intense erythema, edema, and vesiculation necessitating discontinuation of therapy. Patients who are applying alitretinoin should not concurrently use... [Pg.1305]

Taxol is a natural product that has impacted the lives of hundreds of thousands of people. Since 1992, it has been the API in certain chemotherapy agents provided to patients suffering from a variety of cancers and is approved for the treatment of ovarian, breast, non-smaU-ceU lung cancers and AIDS-related Kaposi s sarcoma in over 50 countries. [Pg.145]

Gori A, Caredda F, Franzetti F, Ridolfo A, Rusconi S, Moroni M. Reversible diabetes in patient with AIDS-related Kaposi s sarcoma treated with interferon alpha-23. Lancet 1995 345(8962) 1438-9. [Pg.673]

Northfelt, D. W., Dezube, B. J., Thommes, J. A., et al. Efficacy of PEGylated-liposo-mal doxorubicin in the treatment of AIDS-related Kaposi s sarcoma after failure of standard chemotherapy. J. Clin. Oncol. 15(2) 653-659. 1997. [Pg.373]

In patients with AIDS-related Kaposi s sarcoma, injection of hCG into the lesions has been reported to cause regression in a dose-related manner. [Pg.872]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...